comparemela.com
Home
Live Updates
Transgene anticipates significant progress from immunotherapy pipeline in 2024 and extends financial visibility until Q4 2025 -March 27, 2024 at 12:45 pm EDT : comparemela.com
Transgene anticipates significant progress from immunotherapy pipeline in 2024 and extends financial visibility until Q4 2025 -March 27, 2024 at 12:45 pm EDT
2023 Full-year results and business update Lead program TG4050 to deliver data in 2024. Advancements in other clinical programs and Research and Innovation activity to...
Related Keywords
France ,
Ottawa ,
Ontario ,
Canada ,
John Felitti ,
Frazer Hall Sylvie Berrebi ,
Lucie Larguier ,
Christelle Schwoerer ,
Maud Brandely Talbot ,
Christophe Ancel ,
Transgene Euronext ,
Johnc Bell ,
Carol Stuckley ,
Pedro Romero ,
James Wentworth ,
Alessandro Riva ,
Canadian Oncolytic Virus Consortium ,
Twitter ,
Linkedin ,
Merck Co ,
Transgene Management Committee ,
Astrazeneca ,
University Of Lausanne ,
Euronext Paris ,
European Journal ,
Phasei Delivir ,
Management Committee ,
Chief Executive Officer ,
Chief Scientific Officer ,
Chief Pharmaceutical Operations Officer ,
Qualified Pharmacist ,
Chief Medical ,
Regulatory Officer ,
Chief Financial Officer ,
Chief Business Officer ,
General Counsel ,
Corporate Secretary ,
Chief Human Resources Officer ,
Combined General Meeting ,
Senior Scientist ,
Cancer Therapeutics Program ,
Ottawa Hospital Research Institute ,
Tasly Biopharmaceuticals ,
Artificial Intelligence ,
Risk Factors ,
Universal Registration Document ,
Management Discussion ,
Markets ,
comparemela.com © 2020. All Rights Reserved.